A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy

Trial Profile

A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2014

At a glance

  • Drugs Mitiglinide (Primary) ; Biguanides; CD26 antigen inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Kissei Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Nov 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top